Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of a customized digital adherence tool on retention in care and adherence to antiretroviral treatment in breastfeeding women, children and adolescents living with HIV in Tanzania: a mixed-methods study followed by clinical trials.
Sumari-de Boer IM, Ngowi KM, Swai IU, Masika LV, Maro RA, Mtenga AE, Mtesha BA, Nieuwkerk PT, Reis R, de Wit TFR, Aarnoutse RE. Sumari-de Boer IM, et al. Among authors: de wit tfr. Trials. 2023 Apr 21;24(1):285. doi: 10.1186/s13063-023-07293-1. Trials. 2023. PMID: 37085913 Free PMC article. Clinical Trial.
Predictors of testing history and new HIV diagnosis among adult outpatients seeking care for symptoms of acute HIV infection in coastal Kenya: a cross-sectional analysis of intervention participants in a stepped-wedge HIV testing trial.
Agutu CA, Oduor TH, Hassan AS, Mugo PM, Chege W, de Wit TFR, Sanders EJ, Graham SM. Agutu CA, et al. Among authors: de wit tfr. BMC Public Health. 2022 Feb 11;22(1):280. doi: 10.1186/s12889-022-12711-1. BMC Public Health. 2022. PMID: 35148720 Free PMC article. Clinical Trial.
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Hamers RL, et al. Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27. Lancet Infect Dis. 2012. PMID: 22036233 Clinical Trial.
49 results